Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01670019 · ClinicalTrials.gov registry record · Phase 4

Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression

A Phase 4 study, sponsored by Duke University.

Completed
Registry status
Phase 4
Development phase
46
Enrollment target

NCT01670019 is a Phase 4 study that has completed, run by Duke University. The registered enrollment target is 46 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01670019, a Phase 4 study, has completed, sponsored by Duke University.

COMPLETED
Registry status
Phase 4
Development phase
46 participants
Enrollment target

Study Summary

This is a 6-week comparison of asenapine versus placebo as an add-on to ongoing antidepressant treatment in patients with major depression who have not had a complete therapeutic response to treatment with the antidepressant alone. The investigators hypothesize that added asenapine will produce greater reductions in depression than will added placebo.

Interventions

  • DRUG Asenapine 5-20 mg daily
  • DRUG Placebo 1-4 tablets daily

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2012-10
Est. Completion 2014-06
Phase Phase 4

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT01670019

The ClinicalTrials.gov registry entry for NCT01670019 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Asenapine 5-20 mg daily is the first listed.

NCT01670019 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01670019 about?

NCT01670019 is a clinical study titled "Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression". This is a 6-week comparison of asenapine versus placebo as an add-on to ongoing antidepressant treatment in patients with major depression who have not had a complete therapeutic response to treatment with the antidepressant alone. The investigators hypothesize that added asenapine will produce gre...

What is the current status of trial NCT01670019?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 46 participants. The study started on 2012-10. Estimated completion is 2014-06.

What interventions are being tested in trial NCT01670019?

The interventions under investigation include: Asenapine 5-20 mg daily (DRUG), Placebo 1-4 tablets daily (DRUG).

Who is sponsoring clinical trial NCT01670019?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.